

Azzur Group's Comprehensive Approach:

ELEVATING CLEANING VALIDATION TO TACKLE FDA OBSERVATIONS

By: Harsh Vithlani, Validation Engineer, Azzur Group;
TJ Woody, Director of Cleaning Validation, Azzur Group

AZZUR GROUP

Table of Contents

Executive Summary

Discover Azzur Group's visionary strategy for fortifying pharmaceutical companies' cleaning validation programs in response to critical FDA 483 and Warning Letter observations.

These observations, ranging from high-potency drugs to microbial risks, require a proactive and comprehensive approach. Azzur Group's expertise empowers pharmaceutical manufacturers to surpass regulatory expectations and enhance compliance.

Introduction

In a rapidly evolving regulatory landscape, Azzur Group leads the charge in refining cleaning validation programs to encompass worst case scenarios.

The recent trend in the FDA warning letters underlines the need to refine cleaning validation programs by incorporating worst case scenarios into the assessment process.

These scenarios involve various aspects of drug properties, cleaning methodologies, and microbial risks. This whitepaper provides a comprehensive plan to systematically address these challenges.

The FDA Observations

The FDA's observations emphasize the need for appropriate improvements in cleaning validation programs.

Special emphasis is placed on incorporating conditions identified as worst case in the drug manufacturing operation. Since 2020, more than 60 companies worldwide have been hit with the same observations.

The specific observation is written as follows:

Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst case:

- Drugs with higher toxicities
- Drugs with higher drug potencies
- Drugs of lower solubility in their cleaning solvents
- Drugs with characteristics that make them difficult to clean
- Swabbing locations for areas that are most difficult to clean
- Maximum hold times before cleaning

The FDA Observations Cont.

Drugs with Higher Toxicities and Potencies

- Conduct a risk assessment to identify drugs with elevated toxicities and potencies.
- Develop customized cleaning procedures and acceptance criteria for high-risk drugs.
- Implement segregated equipment or handling high-risk drugs to prevent cross-contamination.

Drugs of Lower Solubility in Cleaning Solvents

- Evaluate solubility characteristics of drugs in cleaning solvents through lab studies.
- Optimize cleaning solvents and procedures to effectively remove residues of poorly soluble drugs.

Drugs with Difficult-to-Clean Characteristics

- Identify drugs with unique properties that hinder effective cleaning.
- Develop tailored cleaning procedures for each challenging drug, potentially involving alternative cleaning agents or extended cleaning cycles.
- Utilize visual inspections and targeted analytical techniques to determine when equipment meets the predetermined carryover limits.

Swabbing Locations and Techniques

- Conduct a comprehensive risk assessment to identify areas posing significant cleaning challenges.
- Develop a comprehensive swabbing plan focusing on critical areas.
- Implement validated swabbing techniques and sampling procedures.
- Define strategic swabbing locations to target challenging areas.

Microbial Risks and Maximum Hold Times

- Evaluate microbial risks tied to equipment and cleaning processes.
- Establish maximum allowable hold times for equipment before and after cleaning to prevent microbial proliferation.
- Implement a robust environmental monitoring system for effective microbial contamination control.

Identifying Worst Case Products for Cleaning Validation

Risk assessment is crucial to identifying worst case products. By deciphering the risk identification, evaluation, prioritization, and selection processes, pharmaceutical companies are enabled to validate their cleaning procedures with justifiable rationale.

STEP 1: RISK IDENTIFICATION

In this step, the goal is to identify products that may pose the highest risks in terms of cleaning validation due to their properties and characteristics.

Let's consider a pharmaceutical company that produces both solid oral tablets and oral liquid products. The risk assessment team gathers information on various products, focusing on factors like toxicity, potency, solubility, and complexity of the drug formulation. *For instance:*

High-toxicity drugs: Products with a narrow therapeutic window and potential severe patient impact in case of inadequate cleaning.

High-potency drugs: Products requiring very small doses, making thorough cleaning crucial to prevent cross-contamination.

Low solubility drugs: Products with low solubility in cleaning solvents may result in residue accumulation.

Complex formulations: Drugs with complex formulations or excipients that could lead to residue adherence.

STEP 2: RISK EVALUATION AND PRIORITIZATION

Based on the collected data, the team evaluates the identified risks and prioritizes them to determine which products should be treated as worst case scenarios.

For instance:

High-toxicity and high-potency drugs: May be assigned high priority due to their potential impact on patient safety.

Low solubility drugs: Could also be high priority as their residues might be challenging to remove effectively.

Complex formulations: Might be given moderate priority, depending on the product's impact on cleaning.

Identifying Worst Case Products for Cleaning Validation Cont.

STEP 3: WORST CASE PRODUCT SELECTION

The products with the highest risk scores are selected as worst case products for cleaning validation for the specific manufacturing equipment. These products will undergo rigorous cleaning validation studies to ensure that the cleaning procedures are effective and can consistently remove residues.

STEP 4: CUSTOMIZED CLEANING PROCEDURES

For each worst case product, the team develops and validates cleaning procedures tailored to the specific challenges posed by the product's properties. This might involve adjusting cleaning agents, cleaning cycles, or new cleaning equipment.

STEP 5: ONGOING MONITORING

Once the worst case products are identified and the cleaning process is developed and validated, ongoing monitoring is essential.

Regularly reviewing and updating the factors that can impact the validated cleaning process is critical to ensuring the process remains in a state of control. Having a procedure to incorporate new equipment and new products onto the manufacturing equipment is critical to ensuring the worst case groupings and carryover limits remain valid.

Risk assessments ensure that new products or changes in manufacturing processes are adequately evaluated for their impact on cleaning validation.

Implementing the Plan

Risk Assessment and Prioritization

Initiate the enhancement process with a detailed risk assessment to identify worst case scenarios arising from drug properties, cleaning methodologies, and microbial vulnerabilities.

Customized Cleaning Procedures

Formulate and validate specialized cleaning procedures tailored to the specifics of each worst case scenario, potentially modifying solvents, cleaning agents, and cycles.

Visual Inspection and Analytics

Seamlessly integrate advanced visual inspection methods and analytical testing to ensure accurate verification of cleanliness, particularly for challenging-to-clean drugs.

Equipment and Facility Controls

Strengthen controls to mitigate cross-contamination risks through dedicated equipment allocation for high-risk drugs. Implement stringent environmental monitoring protocols for managing microbial threats.

Documentation and Reporting

Maintain meticulous records encompassing the entire cleaning validation process, including risk assessments, protocols, and outcomes. Ensure transparent and precise reporting to regulatory bodies.

Conclusion

The recent increase in FDA warning letters only further emphasizes the existing need for organizations to refine their cleaning validation programs.

By providing a holistic and strategic pathway for manufacturers to systematically address their cleaning validation program, this whitepaper aims to demystify the FDA's rigorous expectations.

For more information on how Azzur Group can act as a trusted partner for pharmaceutical, biotechnology, and medical device manufacturers in elevating their cleaning validation program, visit our website.

About Azzur Group

From Discovery to Delivery™, Azzur Group provides the life science community full life-cycle solutions for all of their GxP needs.

From Azzur Cleanrooms on Demand™ facilities, to our labs, training centers, and consulting offices across the nation, Azzur Group helps organizations start, scale, and sustain their growing enterprises. With nearly four decades of service to the life science community, we have become a trusted partner to the world's leading pharmaceutical, biotechnology, medical device, and healthcare companies, as well as their supply chain.

For more resources on this topic, or to learn about solutions Azzur Group provides to organizations in the life science community, visit our website.



About the Author: Harsh Vithlani

Harsh Vithlani is an experienced and certified professional in validation, compliance and quality engineering. With a proven track record in ensuring GMP compliance and optimizing manufacturing processes, Harsh joined Azzur Group in 2021 as a Validation Engineer and is a critical member of the cleaning validation team. Harsh has a master's degree in mechanical engineering with a concentration in pharmaceutical manufacturing from the Stevens Institute of Technology in Hoboken, NJ. Outside of work, he enjoys photography, traveling and playing sports.



About the Author: TJ Woody

TJ Woody leads the Cleaning Validation team at Azzur Group and has 30+ years in the pharmaceutical and biopharmaceutical industries—both working for and within manufacturing companies. His last 15 years have been dedicated to all aspects of cleaning validation from development through validation to periodic monitoring. TJ's hands-on approach takes the theoretical on cleaning topics and makes it compliant and practical for clients.